Novavax, Inc.

NasdaqGS:NVAX Voorraadrapport

Marktkapitalisatie: US$1.2b

Novavax Beheer

Beheer criteriumcontroles 1/4

De CEO Novavax is John Jacobs, benoemd in Jan2023, heeft een ambtstermijn van 1.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.30M, bestaande uit 9.1% salaris en 90.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.03% van de aandelen van het bedrijf, ter waarde $ 347.90K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 4.3 jaar.

Belangrijke informatie

John Jacobs

Algemeen directeur

US$7.3m

Totale compensatie

Percentage CEO-salaris9.1%
Dienstverband CEO1.8yrs
Eigendom CEO0.03%
Management gemiddelde ambtstermijn1.8yrs
Gemiddelde ambtstermijn bestuur4.3yrs

Recente managementupdates

Recent updates

Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Nov 15
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway

Nov 13

Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Nov 01
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Novavax Q3 Earnings A Week Away - Time To Accept A New Reality

Oct 31

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Sep 01

Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Novavax: Staying Long Despite Coming Up Short In Q2

Aug 13

Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal

Jul 26

Novavax: New Chapter, Questions Remain

Jun 20

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14
Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13
Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02
Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01
Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06
Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Analyse CEO-vergoeding

Hoe is John Jacobs's beloning veranderd ten opzichte van Novavax's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$285m

Jun 30 2024n/an/a

-US$294m

Mar 31 2024n/an/a

-US$399m

Dec 31 2023US$7mUS$663k

-US$545m

Compensatie versus markt: De totale vergoeding ($USD 7.30M ) John } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.20M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van John te vergelijken met de prestaties van het bedrijf.

CEO

John Jacobs (57 yo)

1.8yrs

Tenure

US$7,301,009

Compensatie

Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
John Jacobs
President1.8yrsUS$7.30m0.030%
$ 347.9k
John Trizzino
President & COOless than a yearUS$1.88m0.018%
$ 207.2k
James Kelly
Executive VP3.3yrsUS$1.50m0.0090%
$ 105.6k
Mark Casey
Executive VPless than a yearUS$1.53mgeen gegevens
Richard Crowley
Executive VP & COO1.8yrsgeen gegevensgeen gegevens
Robert Walker
Senior VPless than a yeargeen gegevensgeen gegevens
Troy Morgan
Senior VPno datageen gegevensgeen gegevens
Erika Trahan
Associate Director of Investor & Public Relations6.6yrsgeen gegevensgeen gegevens
Ian Watkins
Executive VP & Chief Human Resources Officer1.3yrsgeen gegevensgeen gegevens
Silvia Taylor
Executive VP and Chief Corporate Affairs & Advocacy Officer2.8yrsgeen gegevensgeen gegevens
Elaine O'Hara
Executive VP & Chief Strategy Officer1.8yrsgeen gegevens0.0089%
$ 104.1k

1.8yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NVAX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
John Jacobs
President1.8yrsUS$7.30m0.030%
$ 347.9k
David Mott
Independent Director4.4yrsUS$187.53k0.032%
$ 369.5k
Richard Douglas
Independent Director14.8yrsUS$189.53k0.027%
$ 321.5k
Margaret McGlynn
Independent Director3.9yrsUS$185.02k0.0065%
$ 76.7k
Gregg Alton
Independent Director4.1yrsUS$175.28k0.0065%
$ 76.7k
Rachel King
Independent Director6yrsUS$174.55k0.012%
$ 138.5k
Richard Rodgers
Independent Director2.1yrsUS$191.78k0.0065%
$ 76.7k
James Young
Independent Chairman of the Board14.6yrsUS$222.53k0.039%
$ 452.1k

4.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NVAX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).